Stockscreener 앱 받기
2.93
3.17%
0.09
시간 외 거래:
2.90
-0.03
-1.02%
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
Charles Schwab Investment Management Inc. Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
TELO stock touches 52-week low at $3.1 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $3.1 amid market challenges - Investing.com India
Virtu Financial LLC Acquires Shares of 14,959 Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Bank of New York Mellon Corp Increases Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Analyzing Telomir Pharmaceuticals (TELO) & The Competition - Defense World
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells - Bluefield Daily Telegraph
Telomir Pharmaceuticals announces anti-cancer effects in prostate cancer animal model - MSN
SWK Holdings Announces Monetization of Royalty Portfolio - Waco Tribune-Herald
Telomir-1 shows promise in cancer and chemotherapy study By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Says Telomir-1 Reduces Tumor Size in Prostate Cancer Animal Model - MarketScreener
Telomir-1 shows promise in cancer and chemotherapy study - Investing.com
Telomir Pharmaceuticals reports breakthrough in prostate cancer treatment By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports breakthrough in prostate cancer treatment - Investing.com India
Breakthrough: New Cancer Drug Cuts Prostate Tumors by Half While Reducing Chemo Toxicity - StockTitan
Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows - Benzinga
Rhumbline Advisers Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 34.4% in February - Defense World
Telomir-1 shows promise in reversing cell aging By Investing.com - Investing.com South Africa
Telomir-1 shows promise in reversing cell aging - Investing.com India
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines - Eagle-Tribune
Could This Anti-Aging Compound Revolutionize Treatment for Alzheimer's and Macular Degeneration? - StockTitan
Telomir Pharmaceuticals announces Telomir-1 reverses calcium dysregulation in multiple human cell lines - MSN
Telomir Pharmaceuticals reports key preclinical success By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports key preclinical success - Investing.com India
Telomir Pharmaceuticals achieves breakthrough in silver ion stabilization - MSN
Telomir Pharmaceuticals (NASDAQ:TELO) Research Coverage Started at Rodman & Renshaw - Defense World
Telomir-1 exhibited strong ROS reduction properties, hold potential for AMD treatment - Ophthalmology Times
Telomir reports stabilization of silver forms for medical use By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals Says Telomir-1 Compound Stabilizes Silver for Advanced Medical Applications - Marketscreener.com
Telomir reports stabilization of silver forms for medical use - Investing.com
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market - Weatherford Democrat
Telomir Pharmaceuticals announces silver ion breakthrough - Investing.com
Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration - Benzinga
TELO Again Announces Breakthrough Results - MSN
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD) - Milton Daily Standard
What is Zacks Small Cap's Estimate for TELO Q1 Earnings? - MarketBeat
Telomir Pharmaceuticals (NASDAQ:TELO) Announces Earnings Results, Misses Estimates By $0.05 EPS - MarketBeat
What is Zacks Small Cap’s Estimate for TELO Q1 Earnings? - Defense World
Telomir Pharmaceuticals Inc. (TELO) reports earnings - Quartz
TELO Treatment Amazes in Preclinical Trial - MSN
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts? - Barchart
Telomir Pharmaceuticals Announces Major Breakthrough in Reversing Oxidative Stress, Unlocking Potential for Treating Age-Related Diseases and Viruses Like Bird Flu - Barchart
Thrombotic Thrombocytopenic Purpura Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Global Blood Therapeutics, Sanofi, Carelon Research, Archemix Corp., Eisai Inc - Barchart
10.70%
자본화:
|
볼륨(24시간):